Troy Boutelle Joins MeMed as Vice President of Commercial in North America and General Manager, U.S.
January 12, 2021 07:00 ET
|
MeMed
Troy Boutelle Joins MeMed as Vice President of Commercial in North America and General Manager, U.S. Troy brings 20 years of top-flight sales and commercial experience as MeMed expands into the U.S....
DiaSorin and MeMed partner to develop and commercialize novel host immune response based diagnostics solution
September 08, 2020 07:00 ET
|
MeMed
DiaSorin and MeMed partner to develop and commercialize novel host immune response based diagnostics solution ...
DiaSorin e MeMed avviano una partnership strategica per lo sviluppo e la commercializzazione di una soluzione diagnostica basata sulla risposta immunitaria dei pazienti
September 08, 2020 01:30 ET
|
MeMed
DiaSorin e MeMed avviano una partnership strategica per lo sviluppo e la commercializzazione di una soluzione diagnostica basata sulla risposta immunitaria dei pazienti Accordo di licenza per...
DiaSorin and MeMed partner to develop and commercialize novel host immune response based diagnostics solution
September 08, 2020 01:30 ET
|
MeMed
DiaSorin and MeMed partner to develop and commercialize novel host immune response based diagnostics solution ...
מחקר פורץ דרך שנערך במרכז הרפואי "רבין", בית חולים "השרון", מצא כי לטכנולוגיה של חברת MeMed פוטנציאל לסייע בהתאמת הטיפול התרופתי לחולי קורונה (COVID-19)
July 23, 2020 06:00 ET
|
MeMed
מחקר פורץ דרך שנערך במרכז הרפואי "רבין", בית חולים "השרון", מצא כי לטכנולוגיה של חברת MeMed פוטנציאל לסייע בהתאמת הטיפול התרופתי לחולי קורונה (COVID-19) שימוש בפלטפורמת ה-MeMed Key™, לטובת אבחון מהיר...
Prospective Study Finds Potential Utility of MeMed's Host Immune Technology for Personalizing Treatment of Severe COVID-19 Patients
July 23, 2020 06:00 ET
|
MeMed
Prospective Study Finds Potential Utility of MeMed's Host Immune Technology for Personalizing Treatment of Severe COVID-19 Patients Rapid and Continuous Measurement of the Host-Immune Response with...
Prospective Study Finds Potential Utility of MeMed's Host Immune Technology for Personalizing Treatment of Severe COVID-19 Patients
July 23, 2020 06:00 ET
|
MeMed
Prospective Study Finds Potential Utility of MeMed's Host Immune Technology for Personalizing Treatment of Severe COVID-19 Patients Rapid and Continuous Measurement of the Host-Immune Response with...
前瞻性研究发现 MeMed 的宿主免疫技术对个体化治疗新冠病毒肺炎重症患者具有潜在效用
July 23, 2020 06:00 ET
|
MeMed
前瞻性研究发现 MeMed 的宿主免疫技术对个体化治疗新冠病毒肺炎重症患者具有潜在效用 使用 MeMed Key™ 快速连续地测量宿主免疫应答，有助临床医生预测新冠病毒肺炎的严重程度、监测炎症状态及指导治疗决策 以色列海法，2020 年 7 月 23 日——以色列拉宾综合医学中心（贝林松医院和哈沙隆医院）的研究人员与 MeMed 合作发布前瞻性数据，说明宿主免疫生物标志物 IP-10...
Prospective Study Finds Potential Utility of MeMed's Host Immune Technology for Personalizing Treatment of Severe COVID-19 Patients
July 23, 2020 06:00 ET
|
MeMed
Prospective Study Finds Potential Utility of MeMed's Host Immune Technology for Personalizing Treatment of Severe COVID-19 Patients Rapid and Continuous Measurement of the Host-Immune Response with...
MeMed Receives CE Mark for Two Pioneering Technologies: The MeMed BV™ Test and MeMed Key™ Point-of-Need Platform
June 02, 2020 07:00 ET
|
MeMed
MeMed Receives CE Mark for Two Pioneering Technologies: The MeMed BV™ Test and MeMed Key™ Point-of-Need Platform Cutting-edge instrument platform and a novel host-immune response signature test...